Volume 14 - Issue 7 - July, 2002
Heel Ulcerations in the Diabetic Patient
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 4413 reads
Introduction
Heel ulcers result in a break in the dermal barrier with subsequent erosion of the underlying subcutaneous tissue. As severity increases, the defect extends to muscle and bone, representing one of the most costly, in terms of dollars as well as disability, complications in the elderly. This complication escalates the length of hospital stay and cost of care. The heel is the second leading site for development of pressure ulcers after the sacrum.1
Hospital-acquired heel pressure ulcers represent a significant morbidity and often result in limb loss. Diabetic foot ulceration,
Coumadin-Induced Skin Necrosis
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 25946 reads
Introduction
Coumadin-induced skin necrosis (CISN) is a rare, unusual, and unpredictable integumentary complication of anticoagulant therapy. Also known as warfarin-induced skin necrosis (WISN), the dermatologic complication occurs in 0.01 to 0.1 percent of warfarin-treated patients. As anticoagulation is a component of therapy for many major chronic illnesses, recognition of the condition is crucial for prompt intervention in clinical practice. The syndrome also can result in substantial morbidity and possible fatality. This article addresses the historical background, pathogenesis, clinic
Pyoderma Gangrenosum: Case Report of Novel Treatment with Topical Steroid and Silver Sulfadiazine
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 5713 reads
Introduction
The pathogenesis of pyoderma gangrenosum remains unknown, and because there are no pathognomonic features, the diagnosis is based on clinical grounds. The disease presents as painful, violaceous, boggy, undermined ulcers, most commonly located on the lower extremities. The wounds usually begin as papulovesicles or pustules occurring either spontaneously or after minor trauma. These areas necrose and progress to a confluent ulcer.1 In the majority of cases, pyoderma gangrenosum has been reported in association with a number of systemic diseases, including inflammatory bowel dise
Closure of Partial-Thickness Facial Burns with a Bioactive Skin Substitute in the Major Burn Population Decreases the Cost of Ca
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 5009 reads
Introduction
Management of partial-thickness burns of the face requires extensive healthcare resources, especially in the endotracheal-intubated patient, to control pain, avoid infection, and minimize scarring.1-4
Standard care for partial-thickness burns is the frequent application of antibiotic ointments and cleansing to avoid exudate buildup and infection.3,4 This process is not only time consuming but requires considerable analgesia and involves the potential for endotracheal tube dislodgement with patient movement.
Immediate wound closure of the partial-thickness facial burn can
Special Report: Highlights from the Symposium on Advanced Wound Care and Medical Research Forum on Wound Repair
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 2250 reads
The 15th Annual Symposium on Advanced Wound Care and the 12th Annual Medical Research Forum on Wound Repair (SAWC) were held concurrently at the Baltimore Convention Center in Baltimore, Maryland, April 27-30, 2002. Although the two meetings have been held concurrently for nine years, they have only been one seamless meeting, simply known as the SAWC, for seven years. As always, the meeting was jointly sponsored by HMP Communications (founders of the Symposium on Advanced Wound Care) and the University of Miami (founders of the Medical Research Forum on Wound Repair). For the past seven years,
Evidence Corner
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 2401 reads
Dear Readers:
I would like to introduce a new column entitled Evidence Corner, written by AAWC members. Through this column, we hope to pique interest and provide perspective for new evidence supporting wound care protocols, procedures, and products. We hope you find Evidence Corner a valuable and informative tool as you strive for improved patient outcomes. This month we review a randomized trial of topically applied repifermin and a study of the cost effectiveness of venous and pressure ulcer protocols of care.
Laura Bolton, PhD
Column Editor
Randomized Trial of Topically Appli
July/August
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 2476 reads
FDA-Approved LAM IPM Wound Gel(TM) Sales and Marketing to Begin in Early August 2002
LAM Pharmaceutical, Corp. has completed its plans for the marketing of its wound care product, LAM IPM Wound Gel(TM).
The suggested price of a 10-gram tube (approximately five days supply) will be US $55.00. LAM IPM Wound Gel costs patients (many of whom are reimbursed) less than $12.00 a day.
Distribution specialists are in place to ship and invoice the product to a wide group of potential purchasers including home healthcare organizations; nursing homes; hospital wound care clinics; podiatrists; der
July/August
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 2559 reads
New Arglaes Powder with Controlled-Release Silver for the Care of Chronic Wounds
When Arglaes film dressing featuring controlled release antimicrobial silver was first introduced in the United States a few years ago, physicians at prominent medical facilities, such as New York University Medical Center and Cleveland Clinic Heart Center, called it a significant development in the battle against infection. Arglaes in a powder form was recently launched, and it has greater application in helping to fight antibiotic-resistant bacteria, especially in deep, hard-to-treat wounds. Arglaes has no kn
Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 7401 reads
Department Editor: Tania Phillips, MD, FRCPC
Overall Learning Objectives: The physician or podiatrist participant will develop a rational approach to the evaluation and treatment of a variety of uncommon wounds and will have an increased awareness of the differential diagnosis of cutaneous wounds and the systemic diseases associated with these wounds.
Submissions: To submit a case for consideration in Diagnostic Dilemmas, e-mail or write to: Executive Editor, WOUNDS, 83 General Warren Blvd., Suite 100, Malvern, PA 19355, eklumpp@hmpcommunications.com
Completio
_sm.jpg)
